Crossmark

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Published Online: 2019-12-12

Published Print: 2019-12

Authors

Curtis, Jeffrey R. http://orcid.org/0000-0002-8907-8976
Xie, Fenglong

Kay, Jonathan

Kallich, Joel D
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-12
More Information

Article History

Received: 28 May 2019

Accepted: 3 October 2019

First Online: 12 December 2019

Ethics approval and consent to participate

: The study was approved and governed by the University of Alabama Institutional Review Board and by a Data Use Agreement (DUA) from the Centers for Medicare and Medicaid Services (CMS) (RSCH-2014-27342), a component of the US Department of Health and Human Services (HHS). As this was a retrospective observational cohort study, participants were not required to provide informed consent.

: Not applicable

: JRC – Research Grants and Consulting: AbbVie, Amgen, BMS, Corrona, Eli Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, UCB.FX: NoneJKay: Research Grants (paid to the University of Massachusetts Medical School): Pfizer Inc.; UCB, Inc.Consultant: AbbVie Inc.; Alvotech; Boehringer Ingelheim GmbH; Celltrion Healthcare Co. Ltd.; Merck Sharp & Dohme Corp.; Pfizer Inc.; Samsung Bioepis; Sandoz Inc.; UCB, Inc.JDK: Stock Ownership: Amgen.

Document is current